It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Subanesthetic ketamine is increasingly used for the treatment of varied psychiatric conditions, both on- and off-label. While it is commonly classified as an N-methyl D-aspartate receptor (NMDAR) antagonist, our picture of ketamine’s mechanistic underpinnings is incomplete. Recent clinical evidence has indicated, controversially, that a component of the efficacy of subanesthetic ketamine may be opioid dependent. Using pharmacological functional ultrasound imaging in rats, we found that blocking opioid receptors suppressed neurophysiologic changes evoked by ketamine, but not by a more selective NMDAR antagonist, in limbic regions implicated in the pathophysiology of depression and in reward processing. Importantly, this opioid-dependent response was strongly sex-dependent, as it was not evident in female subjects and was fully reversed by surgical removal of the male gonads. We observed similar sex-dependent effects of opioid blockade affecting ketamine-evoked postsynaptic density and behavioral sensitization, as well as in opioid blockade-induced changes in opioid receptor density. Together, these results underscore the potential for ketamine to induce its affective responses via opioid signaling, and indicate that this opioid dependence may be strongly influenced by subject sex. These factors should be more directly assessed in future clinical trials.
In rats, functional ultrasound imaging reveals that blocking opioid receptors modulates the effects of subanesthetic ketamine on neural activity in males but not in females, with parallel changes in ketamine’s effects on brain structure and behavior.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Stanford University School of Medicine, Department of Radiology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); University of California, San Francisco, Departments of Psychiatry & Behavioral Sciences and Radiology & Biomedical Imaging, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
2 Stanford University School of Medicine, Department of Radiology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
3 National Institute on Drug Abuse Intramural Research Program, Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, Baltimore, USA (GRID:grid.420090.f) (ISNI:0000 0004 0533 7147)
4 National Institute on Drug Abuse Intramural Research Program, Biobehavioral Imaging and Molecular Neuropsychopharmacology Unit, Baltimore, USA (GRID:grid.420090.f) (ISNI:0000 0004 0533 7147); Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311)
5 Stanford University School of Medicine, Department of Radiology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Department of Materials Science and Engineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956); Stanford University School of Medicine, Department of Psychiatry and Behavioral Sciences, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)